Conference Coverage
4 days ago
Day 3 Recap: South Beach Symposium 20265 days ago
Day 2 Recap: South Beach Symposium 2026Latest News
Feb 11, 2026 | News
New Phase 3 DISCREET Data Supports Long-Term Use of Apremilast for Genital Psoriasis
Rethinking Aging in Skin of Color: A Pigment-First Approach
Feb 11, 2026
Journal Digest: February 11, 2026
Feb 11, 2026
What Counts as “Short-Term” Systemic Corticosteroids in Atopic Dermatitis, and Why It Matters
Feb 11, 2026
FDA Updates iPLEDGE REMS with New Modifications for Pregnancy Testing and Prescription Windows
Feb 10, 2026
Advertisement
Shorts
0:45
The Self-Care Evolution in Neuromodulation
12 days ago
by
Bill Andriopoulos, PhD
1:19
Emphasizing SPF in Post-Procedural Care
14 days ago
by
Jennelle Daly, MPAS, PA-C
0:54
EB Simplex: Not a 'Simple' Disease
22 days ago
by
Karen M. McGuire, PhD
0:52
How AI Could Boost Diversity in Dermatology
a month ago
by
Harvey Castro, MD, MBA(+1 more)
0:42
Clinician Collaboration in Dermatology
a month ago
by
Renata Block, DMSc, MMS, PA-C
1:10
Dermatology Times Wrapped 2025
a month ago
by
Dermatology Times Staff
0:34
The Gift of Patient Access
2 months ago
by
Patrick Burnett, MD, PhD
0:31
The Gift of Isotretinoin
2 months ago
by
Hilary Baldwin, MD
0:39
The Gift of Removing Prior Authorizations
2 months ago
by
Peter Lio, MD
0:39
Prior Authorization Denials Lack Transparency
2 months ago
by
John Barbieri, MD, MBA, FAAD
Podcasts
Dermatology Times Digital Edition
The consensus summarizes contemporary real-world data showing that nearly 1 in 5 adolescents and adults with AD receive SCS.
A new molecular test offers clinicians a way to personalize treatment for moderate to severe atopic dermatitis and reduce therapeutic cycling, helping to achieve faster control and a better experience for patients.
Takeda’s recent announcement of positive top-line phase 3 results for zasocitinib (TAK-279) places this investigational agent squarely within that evolving conversation.
Learn more about the in-depth topics covered in the January 2026 print issue of Dermatology Times.
Innovative acne treatments emerge, including sponge-derived therapies and microbiome strategies, promising a brighter future for patients.
Explore the potential of glucagon-like peptide-1 (GLP-1) therapies in dermatology, including inflammatory skin diseases such as psoriasis and hidradenitis suppurativa, to improve patient outcomes.
Tina Alster, MD; Daniel Schlessinger, MD; and Mary Lupo, MD, shared their insights on upcoming aesthetic innovations at the American Society for Dermatologic Surgery Annual Meeting in Chicago, Illinois.
Explore the latest advancements in dermatology for 2026, focusing on clinical innovation, emerging research, and practical insights for improved patient care.
The 2025 Inflammatory Skin Disease Summit (ISDS) unveils innovative therapies and immune profiling strategies, transforming the landscape of dermatological care.
Discover insights from the Horizons in Advanced Practice meeting on type 2 inflammation and psoriasis management.
Continuing Medical Education
All News
Advertisement
Advertisement
Septerna to share phase 1 SEP-631 results at AAAAI, targeting MRGPRX2 to curb mast cell flares and broaden options for refractory CSU.
Catch up on the health and dermatology-related commercials that aired during the 2026 Super Bowl.
REZOLVE-AD shows rezpegaldesleukin delivers durable atopic dermatitis control with monthly or quarterly dosing, supporting Nektar’s phase 3 plans.
Review identifies clinical and lab predictors of early antihistamines CSU and omalizumab CSU response, guiding personalized treatment.
A new molecular test offers clinicians a way to personalize treatment for moderate to severe atopic dermatitis and reduce therapeutic cycling, helping to achieve faster control and a better experience for patients.
In omalizumab-resistant chronic spontaneous urticaria (CSU), tofacitinib rapidly calmed symptoms, but relapses varied.
Victoria Werth, MD, highlights CLE treatment gaps and how BDCA2-targeting litifilimab may quickly curb interferon-driven skin disease with less toxicity.
Takeda’s recent announcement of positive top-line phase 3 results for zasocitinib (TAK-279) places this investigational agent squarely within that evolving conversation.
Bispecific and trispecific biologics are being developed to achieve deeper clearance and more meaningful symptom relief.
Modern hidradenitis suppurativa (HS) management prioritizes restoration of function and quality of life, not just reduction in lesion counts, according to Barry Resnik, MD.
Advertisement
Clinicians are increasingly facing barriers when attempting to prescribe on-label treatments for indicated patients.
Catch up on coverage from the third day of South Beach Symposium 2026.
GLP-1 therapies represent a paradigm shift requiring dermatology to integrate metabolic, medical, and aesthetic care.
At South Beach Symposium 2026, Mona Shahriari explores OX40/OX40L therapies for atopic dermatitis.
Glynis Ablon, MD, FAAD, examines the intersection of menopause, hormones, and dermatologic health.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Updates iPLEDGE REMS with New Modifications for Pregnancy Testing and Prescription Windows
2
Targeting MRGPRX2: Early Human Data for a Novel CSU Approach
3
Precision Medicine Arrives in Atopic Dermatitis: Guiding Systemic Treatment Decisions Through Gene Expression Profiling
4
Phase 3 Results Signal a New Era for Oral Targeted Therapy in Psoriasis
5